R
Raveen Rathnasinghe
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 42
Citations - 2394
Raveen Rathnasinghe is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Medicine & Virus. The author has an hindex of 12, co-authored 30 publications receiving 1037 citations. Previous affiliations of Raveen Rathnasinghe include Mount Sinai Health System.
Papers
More filters
Journal ArticleDOI
Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model.
Fatima Amanat,Shirin Strohmeier,Raveen Rathnasinghe,Michael Schotsaert,Lynda Coughlan,Adolfo García-Sastre,Florian Krammer +6 more
TL;DR: In this paper, the authors test multiple versions of a soluble spike protein for their immunogenicity and protective effect against SARS-CoV-2 challenge in a mouse model that transiently expresses human angiotensin-converting enzyme 2 via adenovirus transduction.
Journal ArticleDOI
A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses.
Weina Sun,Yonghong Liu,Fatima Amanat,Irene González-Domínguez,Stephen McCroskery,Stefan Slamanig,Lynda Coughlan,Victoria C. Rosado,Nicholas Lemus,Sonia Jangra,Raveen Rathnasinghe,Michael Schotsaert,José L. Martínez,Kaori Sano,Ignacio Mena,Bruce L. Innis,Ponthip Wirachwong,Duong Huu Thai,Ricardo Das Neves Oliveira,Rami Scharf,Richard Hjorth,Rama Raghunandan,Florian Krammer,Adolfo García-Sastre,Peter Palese +24 more
TL;DR: In this paper, the NDV vector expressing an optimized spike antigen (NDV-HXP-S) was used to develop a COVID-19 vaccine candidate based on the Newcastle disease virus (NCV) that can be manufactured at high yields in embryonated eggs.
Journal ArticleDOI
Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine*.
Sonia Jangra,Jana De Vrieze,Angela Choi,Raveen Rathnasinghe,Gabriel Laghlali,Annemiek Uvyn,Simon Van Herck,Lutz Nuhn,Kim Deswarte,Zifu Zhong,Niek N. Sanders,Stefan Lienenklaus,Sunil A. David,Shirin Strohmeier,Fatima Amanat,Florian Krammer,Hamida Hammad,Bart N. Lambrecht,Bart N. Lambrecht,Lynda Coughlan,Adolfo García-Sastre,Bruno G. De Geest,Michael Schotsaert +22 more
TL;DR: In this paper, an amphiphilic imidazoquinoline (IMDQ-PEG-CHOL) TLR7/8 adjuvant, consisting of an imidazquinoline conjugated to the chain end of a cholesterol-poly(ethylene glycol) macromolecular amphiphile, was presented.
Journal ArticleDOI
Limited extent and consequences of pancreatic SARS-CoV-2 infection
Verena van der Heide,Sonia Jangra,Phillip Cohen,Raveen Rathnasinghe,Sadaf Aslam,Teresa Aydillo,Daniel Geanon,Diana Z. Handler,Geoffrey Kelly,Brian T. Lee,Adeeb Rahman,Travis Dawson,J. Qui,D. D’souza,Seunghee Kim-Schulze,Julia K. Panzer,Alejandro Caicedo,Irina Kusmartseva,Amanda L. Posgai,Mark A. Atkinson,Randy A. Albrecht,Adolfo García-Sastre,Brad Rosenberg,Michael Schotsaert,Dirk Homann +24 more
TL;DR: In this article , the authors demonstrate that productive infection is strictly dependent on the SARS-CoV-2 entry receptor ACE2 and targets practically all pancreatic cell types, and they also support the notion of diabetes and hyperglycemia as risk factors for an aggravated COVID-19 course.
Journal ArticleDOI
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
Pauline Maisonnasse,Yoann Aldon,Aurélien Marc,Romain Marlin,Nathalie Dereuddre-Bosquet,Natalia Kuzmina,Alec W. Freyn,Jonne L. Snitselaar,Antonio Gonçalves,Tom G. Caniels,Judith A. Burger,Meliawati Poniman,Ilja Bontjer,Virginie Chesnais,Ségolène Diry,Anton Iershov,Adam J. Ronk,Sonia Jangra,Raveen Rathnasinghe,Philip J. M. Brouwer,Tom P. L. Bijl,Jelle van Schooten,Mitch Brinkkemper,Hejun Liu,Meng Yuan,Chad E. Mire,Mariëlle J. van Breemen,Vanessa Contreras,Thibaut Naninck,Julien Lemaitre,Nidhal Kahlaoui,Francis Relouzat,Catherine Chapon,Raphael Ho Tsong Fang,Charlene McDanal,Mary Osei-Twum,Natalie St-Amant,Luc Gagnon,David C. Montefiori,Ian A. Wilson,Eric Ginoux,Godelieve J. de Bree,Adolfo García-Sastre,Michael Schotsaert,Lynda Coughlan,Lynda Coughlan,Alexander Bukreyev,Sylvie van der Werf,Sylvie van der Werf,Jeremie Guedj,Rogier W. Sanders,Rogier W. Sanders,Marit J. van Gils,Roger Le Grand +53 more
TL;DR: In this article, the authors evaluated the in vivo prophylactic and therapeutic effect of COVA1-18, a neutralizing antibody highly potent against the B.1.7 isolate.